Payment overview · 2025
General Payments
$9,227.01
74 reported records · 17 companies
Healthcare provider profile · identity verified
Jean Robey, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · SUN CITY, AZ · NPI 1255377800
Verified facts
What the public records show
CMS Open Payments records show Jean Robey, M.D. received $9,227.01 in general payments during 2025 across 74 reported records.
Travere Therapeutics, Inc. accounted for 81.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Filspari, Jardiance, Kerendia, Tarpeyo, Tavneos.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAVNEOS as an associated drug or biological on 21404 records involving 7606 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tavneos by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 279 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Calliditas Therapeutics US Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TARPEYO as an associated drug or biological on 14378 records involving 5162 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tarpeyo by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Eliquis by this doctor in 2024.
Travere Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Filspari as an associated drug or biological on 8542 records involving 2693 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Filspari by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $7,517.28 | 81.5% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $278.65 | 3.0% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $275.24 | 3.0% | 16 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $206.15 | 2.2% | 2 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $170.69 | 1.9% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $164.55 | 1.8% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $114.93 | 1.2% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $109.21 | 1.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $94.88 | 1.0% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $91.88 | 1.0% | 4 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $71.13 | 0.8% | 3 | 2025 |
| CorMedix Inc. | Unresolved — no canonical attribution shown | $30.96 | 0.3% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $25.15 | 0.3% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.87 | 0.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.26 | 0.2% | 1 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.23 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.95 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $5,000.00 | 2 |
| Food and Beverage | $2,335.54 | 68 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,800.00 | 2 |
| Travel and Lodging | $72.24 | 1 |
| Education | $19.23 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $7,285.83 | 8 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $212.98 | 12 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $209.81 | 9 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $206.15 | 2 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $170.69 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $164.55 | 7 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $91.88 | 4 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $90.37 | 4 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $71.13 | 3 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $62.26 | 4 | 2025 |
Source payment records
|
|||||
| DEFENCATH Normalized: defencath |
Drug | CorMedix Inc. | $30.96 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Filspari filspari |
2025 | Filspari | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TARPEYO tarpeyo |
2025 | Tarpeyo | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TAVNEOS tavneos |
2025 | Tavneos | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TAVNEOS open payments reported associated product |
CMS Open Payments — General Payments 21404 supporting records · 7606 recipient NPIs · example record 1226871817 |
Tavneos · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
279 | 67 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
92 | 47 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Calliditas Therapeutics US Inc. Exact reporting entity; no affiliate inference |
2025 | TARPEYO open payments reported associated product |
CMS Open Payments — General Payments 14378 supporting records · 5162 recipient NPIs · example record 1234989331 |
Tarpeyo · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Travere Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Filspari open payments reported associated product |
CMS Open Payments — General Payments 8542 supporting records · 2693 recipient NPIs · example record 1244395624 |
Filspari · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Farxiga | Dapagliflozin Propanediol | 279 | 67 |
| Losartan Potassium | Losartan Potassium | 174 | 56 |
| Furosemide | Furosemide | 166 | 63 |
| Hydralazine Hcl | Hydralazine Hcl | 159 | 66 |
| Calcitriol | Calcitriol | 145 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 144 | 52 |
| Lisinopril | Lisinopril | 133 | 40 |
| Spironolactone | Spironolactone | 130 | 44 |
| Doxazosin Mesylate | Doxazosin Mesylate | 119 | 34 |
| Potassium Chloride | Potassium Chloride | 119 | 46 |
| Carvedilol | Carvedilol | 115 | 39 |
| Allopurinol | Allopurinol | 95 | 33 |
| Lokelma | Sodium Zirconium Cyclosilicate | 92 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 21 |
| Nifedipine Er | Nifedipine | 70 | 22 |
| Atorvastatin Calcium | Atorvastatin Calcium | 68 | 23 |
| Bumetanide | Bumetanide | 68 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 23 |
| Clonidine Hcl | Clonidine Hcl | 60 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 60 | 21 |
| Prednisone | Prednisone | 55 | 20 |
| Sevelamer Carbonate | Sevelamer Carbonate | 46 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 32 |
| Fluconazole | Fluconazole | 41 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 12 |
| Minoxidil | Minoxidil | 37 | 13 |
| Tramadol Hcl | Tramadol Hcl | 37 | 14 |
| Valsartan | Valsartan | 35 | 12 |
| Kerendia | Finerenone | 33 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 33 | 11 |
| Potassium Citrate Er | Potassium Citrate | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | 11 |
| Velphoro | Sucroferric Oxyhydroxide | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | 13 |
| Cinacalcet Hcl | Cinacalcet Hcl | 28 | 11 |
| Gabapentin | Gabapentin | 26 | 15 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Simvastatin | Simvastatin | 24 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 21 | suppressed |
| Calcium Acetate | Calcium Acetate | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Tacrolimus | Tacrolimus | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Filspari | Sparsentan | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Tarpeyo | Budesonide | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Tavneos | Avacopan | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,227.01 · 74 records | Travere Therapeutics, Inc. | ACTHAR, DEFENCATH, Fabhalta, Filspari, IBSRELA, JARDIANCE, JYNARQUE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, KRYSTEXXA, Kerendia, Ozempic, PAXLOVID, RAYALDEE, TARPEYO, TAVNEOS, VOYXACT, Vafseo | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Filspari play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error